Literature DB >> 25838401

Experimental drug that injured UK volunteers resumes in human trials.

Owen Dyer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25838401     DOI： 10.1136/bmj.h1831

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  3 in total

Review 1.  Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

Authors:  Mariona Cabo; Rienk Offringa; Laurence Zitvogel; Guido Kroemer; Aura Muntasell; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-08-30       Impact factor: 8.110

Review 2.  Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategy.

Authors:  Marina A Dobrovolskaia
Journal:  J Control Release       Date:  2015-09-05       Impact factor: 9.776

Review 3.  Nanoparticle-Induced Complement Activation: Implications for Cancer Nanomedicine.

Authors:  Ninh M La-Beck; Md Rakibul Islam; Maciej M Markiewski
Journal:  Front Immunol       Date:  2021-01-08       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.